Compare AU
Compare DRUG vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 78 |
Median incremental investment | $990.50 | $640.11 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,955.77 | $1,265.40 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | CURE | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 27.78m in AUM and 125 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) | Natera Inc (2.70 %) Vertex Pharmaceuticals Inc (2.67 %) Alnylam Pharmaceuticals Inc (2.64 %) |
Top 3 industries | Other (77.25 %) Communication Services (33.53 %) Health Care (22.59 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.57 % | 0.45 % |
Key Summary
DRUG | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.45 % |
Price | $7.67 | $42.18 |
Size | $166.049 million | $28.786 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.89 % | 4.24 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 78 |
Median incremental investment | $990.50 | $640.11 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,955.77 | $1,265.40 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |